Irritable Bowel SyndromePhase 2NCT02108119
The Effect of Probiotics on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome
A Phase 2 study testing Probiotics in people with Irritable Bowel Syndrome, run by Probi AB at 1 site in Netherlands.
Trial summary
To demonstrate benefit of a probiotic product in adults with irritable bowel syndrome. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Irritable Bowel Syndrome
- What is being tested?
- Probiotics
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 197 participants
- Where
- 1 siteNetherlands
- Study dates
- 2 May 2014to 30 Nov 2015
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Willing and able to provide informed consent
- Age ≥18 and ≤70 years at Visit 1
- IBS according to the Rome III criteria
- A score on abdominal pain NRS ≥3 and ≤6 at least two days a week measured the weeks before Visit 2 (baseline)
- IBS-SSS ≥75 and ≤300 at Visit 2 (baseline)
- Ability and willingness to understand and comply with the study procedures
Who cannot join
- Known intolerance or allergy to milk products (protein or lactose) or gluten
- History of alcohol or substance abuse six months prior to screening
- Known Hepatitis B or C or Human Immunodeficiency Virus (HIV) 1 or 2
- Female patients: currently pregnant or breast-feeding or intending to become pregnant during the study
- Abnormal results of the screening laboratory tests clinically relevant for study participation, as judged by the Investigator
- Other gastrointestinal disease(s) that explains the patient's symptoms, as judged by the Investigator
Show all 13Show fewer
- Other severe disease(s) such as malignancy, severe coronary disease, kidney disease or neurological disease, as judged by the Investigator
- Symptoms indicating other severe disease(s) such as gastrointestinal bleeding, loss of weight or fever, as judged by the Investigator
- Severe psychiatric disease as judged by the Investigator
- Lack of suitability for participation in the study for any reason as judged by the Investigator
- Use of other probiotic products from Visit 1 and throughout the study.
- Consumption of antibiotic drugs 1 month prior to screening and throughout the study.
- Consumption of drugs on a regular basis which could interfere with symptom evaluation as judged by the Investigator.
Trial locations and contacts
1 site in 1 country.
About this study
To demonstrate benefit of a probiotic product in adults with irritable bowel syndrome.
- Conditions
- Irritable Bowel Syndrome
- Being tested
- Probiotics, Control placebo
- Medical subject headings
- Irritable Bowel Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ProbioticsDietary supplement
Control placeboDietary supplement
| Study group | Role | What they receive |
|---|---|---|
| Probiotics | Active comparator | Not described Receives: Dietary Supplement: Probiotics |
| Control placebo | Placebo comparator | Not described Receives: Dietary Supplement: Control placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Abdominal pain
0-10 numeric rating scale (NRS)
Measured: 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Apr 2014 (estimated)
- Study start2 May 2014
- Primary completion30 Nov 2015
- Study completion30 Nov 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Irritable Bowel SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 197 participants (actual)
Sponsor and investigators
- Lead sponsor
- Probi AB
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02108119
- Sponsor's protocol ID
- PRO008
- Status last verified
- Jun 2017
- First submitted
- 1 Apr 2014
- Last updated
- 16 Jun 2017
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jun 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Probiotics on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome
- ClinicalTrials.gov ID
- NCT02108119
- Acronym / sponsor ID
- PRO008
- Conditions
- Irritable Bowel Syndrome
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 197 participants (actual)
- Lead sponsor
- Probi ABIndustry (pharma, biotech, devices)
- Study start
- 2 May 2014 (actual)
- Primary completion
- 30 Nov 2015 (actual)
- Study completion
- 30 Nov 2015 (actual)
- First posted
- 9 Apr 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To demonstrate benefit of a probiotic product in adults with irritable bowel syndrome.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Probiotics | Active comparator | Dietary Supplement: Probiotics |
| Control placebo | Placebo comparator | Dietary Supplement: Control placebo |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Willing and able to provide informed consent
- Age ≥18 and ≤70 years at Visit 1
- IBS according to the Rome III criteria
- A score on abdominal pain NRS ≥3 and ≤6 at least two days a week measured the weeks before Visit 2 (baseline)
- IBS-SSS ≥75 and ≤300 at Visit 2 (baseline)
Key exclusion criteria (13 listed)
- Known intolerance or allergy to milk products (protein or lactose) or gluten
- History of alcohol or substance abuse six months prior to screening
- Known Hepatitis B or C or Human Immunodeficiency Virus (HIV) 1 or 2
- Female patients: currently pregnant or breast-feeding or intending to become pregnant during the study
- Abnormal results of the screening laboratory tests clinically relevant for study participation, as judged by the Investigator
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Probiotics | Dietary supplement | Probiotics |
| Control placebo | Dietary supplement | Control placebo |
Primary outcome
Abdominal pain
Time frame: 28 days
0-10 numeric rating scale (NRS)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jun 2017.
Related trials for Irritable Bowel Syndrome
RecruitingObservational study
Abdominal Symptoms and Rosacea: An Observational Study on the Association Between Irritable Bowel Syndrome (IBS) and the Gut-Skin Axis
IBS (Irritable Bowel Syndrome), Rosacea
Recruiting
Stress Reduction and Lifestyle Modification in Irritable Bowel Syndrome Patients
Irritable Bowel Syndrome
Recruiting
Exercise Interventions and Dietary Advice in Fibromyalgia and IBS
Fibromyalgia, Irritable Bowel Syndrome
RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
Irritable Bowel Syndrome, Constipation
RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
Irritable Bowel Syndrome, Diarrhea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Probiotics in people with Irritable Bowel Syndrome, run by Probi AB at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jun 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Abdominal pain (time frame: 28 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jun 2017.